QUIRÓS, L. P.; UGALDE, R. Analysis of the budgetary impact of alemtuzumab as second-line therapy, compared to natalizumab and fingolimod, in patients previously treated with interferon beta 1b, diagnosed with active relapsing-remitting multiple sclerosis, treated in the Costa Rican social security fund. Global and Regional Health Technology Assessment, [S. l.], v. 6, n. 1, 2019. DOI: 10.33393/grhta.2019.467. Disponível em: https://journals.aboutscience.eu/index.php/grhta/article/view/467. Acesso em: 20 apr. 2024.